Complement C4d ELISA Kit

$1,105.00

The Complement C4d ELISA Assay Kit is an enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative determination of C4d in human plasma. The product is intended for professional use. The result shall not be used for clinical diagnosis or patient management. FOR RESEARCH USE ONLY.

SKU: COMPL C4D Categories: , , , ,

Complement C4d ELISA Kit

Complement C4d ELISA Kit Developed and Manufactured by Svar Life Science

Size: 1×96 wells
Standard Range: 0.3-13.2 ng/ml
Incubation Time: 2 hours
Sample Type: Plasma
Sample Size: 10 µl
For Research Use Only

Controls Included

Assay Background

The complement system plays an essential role in autoimmune and infectious diseases. There are three pathways of complement activation; the classical, the alternative and the lectin pathway. The C4d protein is a product of the classical and the lectin pathways.
C4d, a degradation end product produced during complement C4 activation, had been recognized as a biomarker for its stability and strong association with antibody-mediated rejection in the 1990s and in the last twenty years, the potential importance of C4d in SLE as a tool for diagnosing and monitoring SLE was highlighted (1). Particularly, C4d associates with SLE nephritis (2). In primary Sjogren’s syndrome (pSS) the level of C4d correlates with anti-SSB and κ/λ ratio and is suggested to be an appropriate marker of antibody response and complement activation in pSS patients with auto-antibodies (3,4). Plasma level of C4d has been shown to be significantly higher in patients with antibody–associated vasculitis with active disease compared with patients with lupus nephritis and normal controls (5). Peritubular C4d deposition is a significant predictor of long-term graft survival rates and to be of prognostic significance (6). C4d, is increased in biological samples from lung cancer patient and is associated with poor prognosis of lung cancer at a very early stage (7,8). C4d is increasingly recognized as a potential biomarker where antibodies can cause tissue damage, such as systemic autoimmune diseases. C4d has the potential to detect patients at risk for the consequences of antibody-mediated disease. Furthermore, the development of new therapeutics that block complement activation makes C4d a marker with potential to identify and monitor patients who may possibly benefit from these drugs (9). Complement assays based on detection of linear neoepitopes has been reported to have an advantage compared to conformational epitopes, as it reduces the risk of false positives and increases specificity (10). This complement assay is based on the detection of the short linear C4d neoepitope exposed at the cleavage site of C4 after activation.

Related Products

Complement MBL Pathway ELISA Assay Kit
Complement TCC ELISA Assay Kit
Complement Alternative Pathway ELISA

Additional Information

Assay Principle

The device is a colorimetric sandwich ELISA. Samples are diluted in assay diluent and 100µL diluted sample is transferred to the microtiter wells and incubated at room temperature for 60 minutes. During this first incubation C4d in the sample is captured by the anti-C4d-Neo monoclonal antibody, pre-coated on the surface of the microtiter wells. After washing to remove unbound material, a second horseradish peroxidase (HRP) labelled monoclonal antibody, that binds to both allelic variants of C4d (A and B), is added the to the well. After incubation for 30 minutes the wells are washed again, and a substrate is added and incubated. The color development is stopped after 30 minutes, and the color is measured in a spectrophotometer. The color is directly proportional to the amount of C4d bound to the well. The amount of C4d is determined by comparison to the color development of the calibrator samples.

Package Inserts

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations